| Case Number | 9980 |
| Request Date | 02/02/2024 |
| Completion Date | 22/02/2023 |
Details of the Request
Q1. How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:
- Adalimumab - Humira
- Adalimumab Biosimilar
- Etrasimod
- Filgotinib
- Golimumab
- Infliximab - Remicade
- Infliximab Biosimilar
- Mirikizumab
- Ozanimod
- Risankizumab
- Tofacitinib
- Upadacitinib
- Ustekinumab
- Vedolizumab
Q2 If you are able to link patient treatment to a disease, could you please provide the number of patients treated in the last 3 months for Ulcerative Colitis ONLY with the following biologic drugs:
- Adalimumab - Humira
- Adalimumab Biosimilar
- Etrasimod
- Filgotinib
- Golimumab
- Infliximab - Remicade
- Infliximab Biosimilar
- Mirikizumab
- Ozanimod
- Risankizumab
- Tofacitinib
- Upadacitinib
- Ustekinumab
- Vedolizumab
Details of the Response
Q1. How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:
- Adalimumab - Humira = 58
- Adalimumab Biosimilar = 369
- Etrasimod = 0
- Filgotinib = 5
- Golimumab = 7
- Infliximab - Remicade = 1
- Infliximab Biosimilar = 138
- Mirikizumab = 0
- Ozanimod = 0
- Risankizumab = 21
- Tofacitinib = 13
- Upadacitinib = 22
- Ustekinumab = 111
- Vedolizumab = 80
Q2 If you are able to link patient treatment to a disease, could you please provide the number of patients treated in the last 3 months for Ulcerative Colitis ONLY with the following biologic drugs:
- Adalimumab - Humira = 2
- Adalimumab Biosimilar = 0
- Etrasimod = 0
- Filgotinib = 0
- Golimumab = 0
- Infliximab - Remicade = 0
- Infliximab Biosimilar = 3
- Mirikizumab = 0
- Ozanimod = 0
- Risankizumab = 0
- Tofacitinib = 2
- Upadacitinib = 4
- Ustekinumab = 1
- Vedolizumab = 14



